NCT00046241

Prevention of Seasonal Affective Disorder

A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).

Conditions

• Seasonal Affective Disorder

Interventions

Type	Name	Description
DRUG	Extended-release bupropion hydrochloride

Timeline

• Start date: 2002-09-01
• Primary completion: 2003-06-01
• Completion: 2003-06-01
• First posted: 2002-09-25
• Last updated: 2017-01-23

Locations

51 sites across 2 countries: United States, Canada